Hematopoietic Growth Factors Library
Hematopoietic Growth Factors DMPK and Bioanalytical Services
Erythropoietin (EPO) bioanalysis is defined by a post-translational dimension absent from every compound preceding it in this library: glycosylation. EPO is a 165-amino-acid glycoprotein with three N-linked and one O-linked glycan sites. Its circulating half-life, receptor binding affinity, and immunogenic potential are determined not by amino acid sequence alone but by glycoform composition. The same EPO concentration with different glycosylation patterns has different biological activity. Total protein quantification without glycoform characterization produces an incomplete analytical profile. EPO follows protease-mediated catabolism — not CYP, not UGT — requiring biologic-level bioanalysis via ligand-binding assay or LC-MS surrogate peptide quantification after tryptic digestion.
Creative Proteomics provides glycosylation-aware protein bioanalysis for EPO: glycoform characterization, intact-protein quantification, LC-MS surrogate peptide profiling, protease-mediated catabolism monitoring, and custom hematopoietic growth factor assay development.
Glycosylation Determines ActivityThree N-linked and one O-linked glycan sites control EPO half-life, receptor affinity, and immunogenicity — not captured by protein quantification alone.
Biologic: Not Small MoleculeEPO requires ligand-binding assay or LC-MS surrogate peptide — standard small-molecule LC-MS/MS methods do not apply.
Protease-Mediated CatabolismEPO is degraded by proteases, not CYP or UGT. Protein-level clearance monitoring requires biologic-specific workflows.
EPO Glycosylation & Bioanalysis DMPK Strategy Map
⚡
Glycoform CharacterizationEPO has 3 N-linked + 1 O-linked glycan sites. Glycosylation determines half-life, receptor binding, and immunogenicity — intact-mass or glycopeptide analysis required.
🧬
Protein-Level BioanalysisLigand-binding assay (ELISA/ECL) for intact EPO or LC-MS surrogate peptide quantification after tryptic digestion — biologic methods, not small-molecule.
📊
Protease-Mediated CatabolismEPO is degraded by proteases in vivo. In vivo sample analysis with protease-stabilized collection for intact-protein quantification.
🔬
Glycosylation + Protein = Complete ProfileTotal EPO concentration without glycoform data is an incomplete analytical readout — two dimensions required for one biologic.
EPO glycosylation-aware bioanalysis.Creative Proteomics combines intact-protein quantification with glycoform characterization — because EPO concentration alone does not describe EPO activity. The same concentration with different glycosylation patterns has different biological behavior.
